[ Double - blind placebo - controlled study of the <font color="blue">effectiveness_5</font> <font color="blue">and_4</font> <font color="blue">tolerability_5</font> <font color="blue">of_1</font> <font color="blue">10_1</font> <font color="blue">and_1</font> <font color="blue">30_1</font> <font color="blue">mg_1</font> <font color="blue">ketorolac_1</font> tromethamine suppositories in <font color="blue">post_2</font> <font color="blue">-_2</font> <font color="blue">cholecystectomy_2</font> <font color="blue">pain_2</font> <font color="blue">]_2</font> . 
<br>
<br> OBJECTIVE To evaluate the efficacy and tolerability of ketorolac tromethamine 10 mg and 30 mg suppositories in comparison to placebo , after single dose administration in patients suffering from <font color="blue">post_1</font> <font color="blue">-_1</font> <font color="blue">operative_1</font> <font color="blue">pain_1</font> after cholecystectomy . 
<br> DESIGN Double - blind , randomized , controlled study . 
<br> SETTING Anaesthesia Service . 
<br> PATIENTS 99 patients with severe pain following surgery . 
<br> INTERVENTIONS Cholecystectomy . 
<br> MEASUREMENTS AND MAIN RESULTS The <font color="blue">analgesia_1</font> activity of ketorolac tromethamine 10 mg and 30 mg suppositories were evaluated after single dose administration by assessing <font color="blue">pain_4</font> <font color="blue">intensity_4</font> <font color="blue">and_4</font> <font color="blue">pain_4</font> <font color="blue">relief_4</font> <font color="blue">using_1</font> <font color="blue">a_1</font> <font color="blue">4_2</font> <font color="blue">point_2</font> <font color="blue">scale_2</font> <font color="blue">(_2</font> <font color="blue">VRS_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> At the end of the treatment period <font color="blue">overall_1</font> <font color="blue">assessment_1</font> <font color="blue">of_1</font> <font color="blue">safety_4</font> <font color="blue">and_4</font> <font color="blue">efficacy_4</font> <font color="blue">were_1</font> <font color="blue">recorded_1</font> <font color="blue">by_1</font> <font color="blue">physician_1</font> <font color="blue">and_1</font> <font color="blue">patient_1</font> <font color="blue">._1</font> The results show that in both active groups after 30 ' and until 4 hours , <font color="blue">pain_5</font> <font color="blue">intensity_4</font> <font color="blue">decreased_1</font> significantly with respect to the baseline . However a statistically significant difference between groups of p < 0.02 , p < 0.01 and p < 0.05 was found in favour of the 30 mg dose respectively at 30 ' , 6 and 8 hours after administration . All the patients treated with placebo suppositories required another <font color="blue">rescue_1</font> <font color="blue">analgesic_1</font> <font color="blue">drug_1</font> and <font color="blue">withdrew_1</font> <font color="blue">from_1</font> <font color="blue">the_1</font> <font color="blue">trial_1</font> <font color="blue">._1</font> Three patients <font color="blue">complained_1</font> <font color="blue">adverse_3</font> <font color="blue">events_3</font> not related to treatment : two on placebo and one on ketorolac 10 mg . The <font color="blue">systemic_1</font> <font color="blue">and_1</font> <font color="blue">local_1</font> <font color="blue">tolerability_1</font> of the drug was good . 
<br> CONCLUSIONS This study shows that <font color="blue">ketorolac_1</font> <font color="blue">30_1</font> <font color="blue">mg_1</font> <font color="blue">suppositories_1</font> <font color="blue">are_1</font> <font color="blue">effective_1</font> <font color="blue">in_1</font> <font color="blue">clinical_1</font> <font color="blue">conditions_1</font> <font color="blue">,_1</font> such as after surgery , in which <font color="blue">pain_1</font> <font color="blue">control_1</font> must be achieved within the shortest time interval and maintained or improved by means of a single route of administration .